Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06059209 · ClinicalTrials.gov registry record · NA
Enfamil NeuroPro Study
A NA study of Infant Development and Infant ALL, sponsored by University of Arizona.
- Active
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT06059209: Active NA study of Infant Development and Infant ALL, sponsored by University of Arizona.
NCT06059209 is a NA study of Infant Development and Infant ALL that is active but no longer recruiting, run by University of Arizona. The registered enrollment target is 240 participants, below the 395-participant average among 30 other Infant Development trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06059209, a NA study of Infant Development and Infant ALL, is active but no longer recruiting, sponsored by University of Arizona.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare infant gut bacteria for infants who have been fed a standard infant formula (Enfamil Infant); infants who have been fed a new infant formula designed to be more similar to breast milk (Enfamil NeuroPro); and breastfed infants. These formulas are currently available on the market and meet FDA requirements for infant formula.
Primary Outcome
Assessed using 16S amplicon profiling of stool samples
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Enfamil NeuroPro
- DIETARY_SUPPLEMENT Enfamil Infant
Study Locations (1)
Arizona
- University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-01-05 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
What the registry record for NCT06059209 still lists
NCT06059209 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 395-participant average among 30 other Infant Development trials with a reported enrollment target (39% lower).
The record links to 2 conditions, with Infant Development appearing as the primary indexed condition, and to 2 interventions - of which Enfamil NeuroPro is the first listed.
NCT06059209 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06059209 about?
NCT06059209 is a clinical study titled "Enfamil NeuroPro Study". This study will compare infant gut bacteria for infants who have been fed a standard infant formula (Enfamil Infant); infants who have been fed a new infant formula designed to be more similar to breast milk (Enfamil NeuroPro); and breastfed infants. These formulas are currently available on the mar...
What is the current status of trial NCT06059209?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2023-01-05. Estimated completion is 2026-05-31.
What conditions does trial NCT06059209 study?
This clinical trial studies the following conditions: Infant Development, Infant ALL.
What interventions are being tested in trial NCT06059209?
The interventions under investigation include: Enfamil NeuroPro (DIETARY_SUPPLEMENT), Enfamil Infant (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06059209?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06059209 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infant Development
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06059209's enrollment target sits among peer trials
240 10th of 30 higher than 21 of 30 other Infant Development trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infant Development trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Walnuts as an Infant Solid Food for Health
RECRUITING · NA
-
Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants
RECRUITING · NA
-
The Impact of Music Medicine on Preterm Brain Development and Behavior
RECRUITING · NA
-
Intervening With Opioid-Dependent MothersMothers and Infants
RECRUITING · NA
-
Investigating Baby Behavior and Family Technology Use Study
RECRUITING · NA
-
Investigating Fit and Satisfaction of the Prone Positioner
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI